Xiaolin Zhang

Xiaolin Zhang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SYShaojie Yang
Shaojie Yang
SWShuodong Wu
Shuodong Wu
WDWanlin Dai
Wanlin Dai
LPliwei pang
liwei pang
YXYaofeng Xie
Yaofeng Xie
JKJing Kong
Jing Kong
Cancer remains a major public health threat. The mitigation of the associated morbidity and mortality remains a major research focus. From a molecular biological perspective, cancer is defined as uncontrolled cell division and abnormal cell growth caused by various gene mutations. Therefore, there remains an urgent need to develop safe and effective antitumor drugs. The antitumor effect of plant extracts, which are characterized by relatively low toxicity and adverse effect, has attracted significant attention. For example, increasing attention has been paid to the antitumor effects of tetramethylpyrazine (TMP), the active component of the Chinese medicine Chuanqiong, which can affect tumor cell proliferation, apoptosis, invasion, metastasis, and angiogenesis, as well as reverse chemotherapeutic resistance in neoplasms, thereby triggering antitumor effects. Moreover, TMP can be used in combination with chemotherapeutic agents to enhance their effects and reduce the side effect associated with chemotherapy. Herein, we review the antitumor effects of TMP to provide a theoretical basis and foundation for the further exploration of its underlying antitumor mechanisms and promoting its clinical application.

12 November 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DCDi Cao
Di Cao
XZXiaolin Zhang
Xiaolin Zhang
MLMingjun Liu
Mingjun Liu
QYQiguang Yang
Qiguang Yang
SGShuhong Gu
Shuhong Gu
SCShaotao Chen
Shaotao Chen
Introduction: The incidence of stroke sequelae among patients is as high as 70%–80%. Flexor spasm is the most common stroke sequela, presenting a heavy burden to the patients and their families. This study will evaluate the results of randomized controlled trials to determine the efficacy and safety of hand manipulation acupuncture for the treatment of upper limb motor dysfunction after stroke.Methods: Eight databases, including China National Knowledge Infrastructure, Chinese Scientific Journal Database, Cochrane Central Register of Controlled Trials, Embase, MEDLINE, PubMed, Wanfang Database, and Web of Science, will be searched using English and Chinese search strategies. In addition, manual retrieval of research papers, conference papers, ongoing experiments, and internal reports, among others, will supplement electronic retrieval. All eligible studies published on or before January 15, 2021 will be selected. To enhance the effectiveness of the study, only clinical randomized controlled trials related to the use of manual acupuncture for the treatment of upper limb motor dysfunction after stroke will be included.Analysis: The Fugl-Meyer upper extremity assessment will be the primary outcome measure, whereas the Wolf Motor Function Test, Modified Ashworth Scale, arm movement survey test table, and upper extremity freehand muscle strength assessment scores will be the secondary outcomes. Side effects and adverse events will be included as safety evaluations. To ensure the quality of the systematic evaluation, study selection, data extraction, and quality assessment will be independently performed by two authors, and a third author will resolve any disagreement.Ethics and dissemination: This systematic review will evaluate the efficacy and safety of manual acupuncture for the treatment of upper limb motor dysfunction after stroke. Since all included data will be obtained from published articles, it does not require ethical approval and will be published in a peer-reviewed journal.INPLASY registration number: INPLASY202110071.

21 August 2020 in Medicine
Verified
Journal Article
Open access
XZXiaolin Zhang
Xiaolin Zhang
DCDi Cao
Di Cao
MYMinhui Yan
Minhui Yan
MLMingjun Liu
Mingjun Liu
Background: At present, metformin is mainly used in the treatment of type 2 diabetes mellitus (T2DM). When the therapeutic effect is achieved, there are side effects and secondary failure will occur if taken for a long time. It is of great significance to actively explore the clinical scheme of reducing drug use while ensuring the therapeutic effect of T2DM. Objective: To evaluate the feasibility of Chinese massage (CM) in the treatment of T2DM. Methods: Literature retrieval is divided into 2 aspects: Electronic Retrieval and Personal Check. We will search PubMed, EMBASE, CNKI, Cochrane Central, which were registered in international clinical trials registry platform systems, select all eligible studies published before November 2, 2019, and use Personal Check method to retrieve papers, conference papers, ongoing experiments, internal reports, and so on. With fasting blood glucose, 2-hour fasting blood glucose, glycosylated hemoglobin, and insulin index as the main observation indexes, we also pay attention to traditional Chinese medicine syndrome score scale, insulin resisting index, body mass index , serum total cholesterol, Curative effect and the occurrence of all adverse reactions in drug treatment. Of the research group 2 researchers respective selected literature, extracted data, and evaluated the risk of bias. After that we used Revman 5.7 and Stata 12.1 statistical software for meta-analysis. Results: A total of 769 subjects were included in 10 studies for meta-analysis. Compared with metformin hydrochloride tablets, CM plus baseline treatment can reduce fasting plasma glucose (weighted mean difference [WMD] = −0.33, 95% confidence interval [CI] [−0.54, −0.13], Z = 3.15, P = .002), 2 hours postprandial blood glucose (WMD = −0.52, 95% CI [−0.70, −0.34), Z = 5.66, P < .00001], hemoglobin A1c (WMD = 0.12, 95% CI [0.04, 0.20], Z = 2.94, P = .003), fasting insulin (WMD = −3.59, 95% CI [−5.56, −1.42], Z = 10.29, P < .00001), traditional Chinese medicine syndrome score scale (WMD = −4.55, 95% CI [−7.58, −1.51], Z = 2.94, P = .003), homeostasis model assessment of insulin resistance (WMD = −1.76, 95% CI [−2.25, −1.27), Z = 7.08, P < .00001), body mass index (WMD = −1.28, 95% CI [−1.65, −0.92], Z = 6.91, P < .00001), serum total cholesterol (WMD = −1.01, 95% CI [−1.14, −0.83], Z = 15.51, P < .00001), meanwhile, the effective rate was increased (risk ratio [RR] = 1.31, 95% CI [1.21, 1.42], Z = 6.57, P < .00001). Conclusion: CM combined with metformin hydrochloride tablet has a synergistic effect. It can not only be used as an auxiliary treatment of T2DM, but also as an important reference way of reducing drug treatment of T2DM, improving Clinical Efficacy and reducing adverse reactions. Systematic review registration: PROSPERO CRD42020158839

18 November 2022 in Medicine
Verified
Journal Article
Open access
SLSiyuan Lei
Siyuan Lei
FDFangran Dai
Fangran Dai
FXFei Xue
Fei Xue
GHGuanyu Hu
Guanyu Hu
YZYe Zhang
Ye Zhang
YWYufeng Wang
Yufeng Wang
Background: To provide evidence, this review evaluated the methodological quality, risk of bias, and reporting quality of SRs/MAs in the treatment of shoulder-hand syndrome after stroke with acupuncture. Methods: Systematic reviews and Meta analyses (SRs/MAs) of acupuncture for shoulder and hand syndromes after stroke were retrieved from 6 databases from inception to May 1, 2022. Two reviewers independently screened the literature and extracted the data, then used Assessment of Multiple Systematic Reviews-2 (AMSTAR-2), Bias Risk in Systematic Review (ROBIS), and Preferred Report Item for Systematic review and Meta–analysis (PRISMA), Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to assess methodological quality, risk of bias, quality of reporting, and quality of evidence. Results: We included 7 SRs/MAs, of which all SRs/MAs had very low AMSTAR-2 assessment quality and one study had a very low assessment bias risk. According to the PRISMA checklist, Protocol and registration, Synthesis of results, Summary of evidence, Conclusions and Funding were the main reporting limitations. GRADE evaluation showed a total of 37 results, but no high-quality evidence results, 6 results (16.22%) of the evidence quality were moderate, and supported acupuncture combined with exercise rehabilitation and drug therapy was better than exercise joint drug rehabilitation and rehabilitation, we also found that the result of limitations were the main factors that influence the evidence of low quality, followed by imprecision, inconsistency, and publication bias. Conclusions: Acupuncture is a relatively safe and effective adjuvant therapy for shoulder and hand syndromes after stroke. However, because of the low quality of SRs/MAs evidence supporting these findings, high-quality randomized controlled trials should be conducted, and the quality of relevant SRs should be improved to provide evidence for clinical application.

24 July 2020 in Medicine
Verified
Journal Article
Open access
XZXiaolin Zhang
Xiaolin Zhang
DCDi Mm Cao
Di Mm Cao
JLJunnan Mm Liu
Junnan Mm Liu
QZQi Zhang
Qi Zhang
MLMingjun Liu
Mingjun Liu
Background: The novel coronavirus pneumonia (COVID-19) has spread to >200 countries and regions. There is no effective antiviral drug for COVID-19. Traditional Chinese medicine, such as Lianhua Qingwen, has achieved some curative effect in many countries, but its effect is not clear. We aim to assess the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection. Methods: The following electronic bibliographic databases will be searched to identify relevant studies: CNKI, CBM, VIP and Wanfang databases, PubMed, EMBASE, MEDLINE, Cochrane central, and clinical trial registration centers, such as China Clinical Trial Registration Center (ChiCTR), Netherlands National Trial Registration Center (NTR) and clinical trials.gov. In addition, Manual retrieval of articles, conference papers, ongoing experiments, internal reports, among others, to supplement electronic retrieval. Select all eligible studies published before May 8, 2020. According to the Cochrane Handbook “bias risk” assessment tool, bias risk is independently assessed. The independent Newcastle Ottawa scale was used to conduct methodological quality assessment of nonrandomized trials. STATA15.1 and RevMan5.3 software were used to analyze meta outcomes of different intervention measures for the treatment of new crown pneumonia and the control group (conventional antiviral western medicine treatment) clinical efficacy. Results: This study will provide a relatively high-quality synthesis of current evidence of Lianhua Qingwen combined with Conventional antiviral Western Medicine in the treatment of COVID-19 from several aspects including the Clinical effective rate, CT improvement rate, severe conversion rate, antipyretic time, disappearance rate of fever symptoms, disappearance rate of cough symptoms, disappearance rate of asthenia symptoms, and adverse drug events. Conclusion: The conclusion of this review will provide evidence to judge whether Lianhua Qingwen combined with Conventional antiviral Western Medicine is an effective and safe intervention for COVID-19. Ethics and dissemination: This systemic review will evaluate the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in the treatment of COVID-19. Since all the data included are published, the systematic review does not need ethical approval. INPLASY registration number: INPLASY202060067

28 January 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
XZXiaolin Zhang
Xiaolin Zhang
DCDi Cao
Di Cao
JLJunnan Liu
Junnan Liu
QZQi Zhang
Qi Zhang
MLMingjun Liu
Mingjun Liu
Introduction About 85% of stroke survivors have upper extremity dysfunction, and more than 60% have continuing hand dysfunction and cannot live independently after treatment. Numerous recent publications have explored brain-computer interfaces technology as rehabilitation tools to help subacute and chronic stroke patients recover upper extremity movement. Our study aims to synthesise results from randomised controlled trials to assess the effectiveness and safety of brain-computer interface technology in the treatment of poststroke motor disorders(PSMD). Methods and analysis English and Chinese search strategies will be conducted in eight databases: the China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, China Doctoral Dissertations Full-Text Database, China Master’s Theses Full-Text Database, Cochrane Central Register of Controlled Trials, PubMed and Embase. In addition, manual retrieval of research papers, conference papers, ongoing experiments and internal reports, among others, will supplement electronic retrieval. The searches will select all eligible studies published on or before 8 June 2020. To enhance the effectiveness of the study, only randomised controlled trials related to brain-computer interface technology for poststroke motor disorders will be included. The Fugl-Meyer Motor Function score will be the primary outcome measure; the Modified Barthel Index, Modified Ashworth Score and the upper extremity freehand muscle strength assessment will be secondary outcomes. Side effects and adverse events will be included as safety evaluations. To ensure the quality of the systematic evaluation, study selection, data extraction and quality assessment will be independently performed by two authors, and a third author will handle any disagreement. Review Manager V.5.3.3 and STATA V.15.1 will be used to perform the data synthesis and subgroup analysis. Ethics and dissemination This systemic review will evaluate the efficacy and safety of brain-computer interface technology combined with routine rehabilitation treatment for treatment of poststroke motor disorders. Since all included data will be obtained from published articles,the review does not require ethical approval. The review will be published in a peer-reviewed journal. PROSPERO registration number CRD42020190868.